Documentos de Dorado P. | REDI

Regresar

Mostrando 10 resultados de: 15

Filtros aplicados

Publisher: "Pharmacogenomics Journal"

Subtipo de publicación

Área temáticas

Farmacología y terapéutica(11)

Enfermedades(9)

Fisiología humana(3)

Cultura e instituciones(2)

Área de conocimiento

Farmacología(4)

Psicopatología(3)

Trastorno depresivo mayor(1)

Año de Publicación

Origen

Palabras Claves

pharmacogenetics(5)

Mexican-Americans(2)

Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population

Abstract: Risperidone non-compliance is often high due to undesirable side effects, whose development is in pa

Palabras claves:

Adverse events, Antipsychotic, pharmacogenetics, Risperidone

Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Baca-García E., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Lopez-Castroman J., Riveiro-Alvarez R., Vaquero-Lorenzo C.

CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards

Abstract: Earlier we had found that the CYP2C9*2 allelic frequency was lower in Mexican-Americans living in Ca

Palabras claves:

CYP2C9, Hispanics, Mexican-Americans, Mexican-Mestizos, Mexican-Tepehuanos, pharmacogenetics

Adrián LLerena, Alanis-Bãuelos R.E., Dorado P., Lares-Asseff I., Licinio J., Penãs-Lledó E.M., Sosa-Macías M.G., Wong M.L.

CYP2C9 gene and susceptibility to major depressive disorder

Abstract: Alteration of monoaminergic neurotransmission has been implicated in the pathophysiology of mood dis

Palabras claves:

CYP2C9 gene, Depression, Schizophrenia

Adrián LLerena, Berecz R., De la Rubia A., Dorado P., González A.P., Penãs-Lledó E.M.

CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy

Abstract: We aimed to explore the possible influence of CYP2C9 (∗2, ∗3 and IVS8-109 A>T), CYP2C19 (∗2, ∗3 and

Palabras claves:

Adrián LLerena, Dorado P., Familiar-López I., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.

CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans

Abstract: CYP2D6 genotype and debrisoquine metabolic ratio (MR) were analyzed in 133 Nicaraguan Mestizos (NMs)

Palabras claves:

Cubans, CYP2D6, debrisoquine hydroxylation, Latinos, Nicaraguans, Phenotype

Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Penãs-Lledó E.M., Pérez B., Ramirez R.

CYP2D6 polymorphism in patients with eating disorders

Abstract: CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is,

Palabras claves:

CYP2D6, Eating disorders, pharmacogenetics, Ultrarapid metabolizers

Adrián LLerena, Agüera Z., Dorado P., Estivill X., Fernández‐aranda F., Gratacòs M., Penãs-Lledó E.M.

Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: Influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms

Abstract: Pharmacogenetic studies have shown that genetic defects in drug-metabolizing enzymes encoded by CYP2

Palabras claves:

CYP2C19, CYP2C9, Epilepsy, Neurological toxicity, paediatric, Phenytoin

Adrián LLerena, Dorado P., López-Torres E., Martínez-Antón J., Penãs-Lledó E.M.

High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina

Abstract: A twofold higher frequency of CYP2D6 ultrarapid metabolizers (estimated from genotype: gUMs) was rep

Palabras claves:

Adrián LLerena, Dorado P., Ferreiro V., Moya G.E., Naranjo M.E.G., Penãs-Lledó E.M.

Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico

Abstract: We previously documented the lowest frequency of CYP2C9*2 in Mexican indigenous Tepehuanos followed

Palabras claves:

ancestral components, CYP2C9, Mexican indigenous, pharmacogenetics

Adrián LLerena, Dorado P., Galaviz-Hernandez C., Lazalde-Ramos B.P., Licinio J., Martínez-Fierro M.L., Martínez-Sevilla V.M., Rangel-Villalobos H., Salazar-Flores J., Sosa-Macías M.G., Wong M.L.

Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy

Abstract: Genetic and nongenetic factors may contribute to lamotrigine (LTG) plasma concentration variability

Palabras claves:

Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.